This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Sep 6;8(10):567.

doi: 10.1038/nrclinonc.2011.115.

Targeted therapies: Should we be aghast at the AVAGAST data?

PMID: 21894207
DOI: 10.1038/nrclinonc.2011.115

Comment

Targeted therapies: Should we be aghast at the AVAGAST data?

Rebecca Kirk. Nat Rev Clin Oncol. 2011.

. 2011 Sep 6;8(10):567.

doi: 10.1038/nrclinonc.2011.115.

Author

PMID: 21894207
DOI: 10.1038/nrclinonc.2011.115

No abstract available

PubMed Disclaimer

Comment on

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Ohtsu A, et al. J Clin Oncol. 2011 Oct 20;29(30):3968-76. doi: 10.1200/JCO.2011.36.2236. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844504 Clinical Trial.

References

1. J Clin Oncol. 2011 Oct 20;29(30):3968-76 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.